Most material SEC filings — October 16, 2026

MiniMed Group completed its spin-off from Medtronic on October 15, 2026. Medtronic exchanged 55,032,401 of its ordinary shares for 252,813,348 MiniMed common shares (5.4x subscription ratio), eliminating its equity stake. MiniMed is now a fully independent publicly-traded company focused on diabetes care and insulin delivery across 80 countries.

Aether Holdings, Inc. (total assets $4.6M) filed an 8-K on October 16, 2026 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing does not specify which exchange, the specific listing standard violated, or remediation timeline, but indicates the company has failed to meet continued listing requirements.

On October 12, 2026, Callan JMB Inc. (market cap ~$7.4M) received notice of delisting or failure to satisfy continued listing requirements. The 8-K filing on October 16, 2026 discloses Item 3.01 (delisting notice) and Item 9.01 (exhibits), but specific details regarding the delisting reason, timeline, cure period, or remediation steps are not provided in this filing excerpt.

eHealth, Inc. received a Notice of Delisting or Failure to Satisfy Continued Listing Standards on October 14, 2026. The filing indicates the company has failed to meet listing requirements; specific compliance failures and remediation timelines are not detailed in this 8-K filing header. This represents a critical regulatory development for the $126.2M market-cap company.

Health In Tech, Inc. (market cap ~$12.7M) received a notice of delisting or failure to satisfy continued listing standards on October 12, 2026, as reported in this October 16, 2026 8-K filing. The filing indicates Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing) but provides no specific details on which listing requirement was violated, the exchange involved, cure timeline, or remediation plan.

On October 12, 2026, Lucid Diagnostics Inc. received notification of failure to satisfy continued listing standards (Item 3.01). The filing does not specify the exact listing rule violated, the exchange involved, cure periods, or any financial details. No counterparties, dollar amounts, or specific remediation steps are disclosed in this 8-K.

Bridgeline Digital (market cap ~$17.4M) received a notice of failure to satisfy continued listing rules. Item 3.01 indicates a delisting notice or listing standard violation was triggered as of October 14, 2026. The filing provides no specific details on the underlying violation, remediation timeline, or financial impact figures.

Amendment No. 2 to the Trademark and Recipe License Agreement between VCP IP Holdings, LLC (Licensor) and GTI Core, LLC (Licensee), effective October 13, 2026, increases the annual license fee for calendar year 2026 to $64,250,000 (payable monthly at $5,354,166.67). The 2027 fee is projected at $67,334,000 with a 4.8% CPI adjustment. The amendment also restricts the Señorita IP trademark to state-regulated dispensary channels only, with Licensor retaining exclusive rights to provide services outside those channels.

SITE Centers Corp. (market cap ~$600M) filed a Form 8-K on October 16, 2026, reporting Item 3.01—Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing indicates the company has received a delisting notice, but the specific listing exchange, reasons for non-compliance, remediation plan, and timeline are not detailed in the document header provided.

Fractyl's REMAIN-1 pivotal trial (n=308) achieved its pre-specified 6-month co-primary endpoint with high statistical significance (p=0.0023). Revita-treated patients maintained 80% of GLP-1-induced weight loss versus 67% in sham controls (5.1% vs 8.2% regain). Post-hoc analysis showed patients with ≥20 cm duodenal ablation regained only 3.8% body weight vs 8.2% sham (53% reduction; p=0.003). No device- or procedure-related serious adverse events observed. De Novo FDA submission planned late Q4 2026; potential US launch early 2028.

Clear Channel Outdoor Holdings filed an amended 8-K (8-K/A) on October 16, 2026, reporting a change in control of the registrant as of October 14, 2026. The filing provides no specific details regarding counterparties, transaction value, share counts, or the mechanism of control change—only that Item 5.01 (Changes in Control) was triggered. Without concrete transaction details in the amendment, the material substance cannot be determined from this filing alone.

Director POHLAD ROBERT C (PEP) bought 185K shares (~$23.7M) on the open market (30% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner NIPPON LIFE INSURANCE CO (CRBG) bought 602K shares (~$20.5M) on the open market (0.5% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner EEME Energy SPV I, LLC (SAFX) bought 119.4M shares (~$142.1M) on the open market (34% of holdings). Open-market insider purchase — historically a bullish signal.

Canopy Growth Corp (CIK 0001737927) filed an 8-K on October 16, 2026, reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing documents the notice itself but does not provide specific details regarding which listing standard was not met, the exchange involved, remediation timeline, or financial metrics that triggered the notice.

On 4 February 2026, Loop Industries, Inc. entered into a Marketing Agreement and License Agreement with Ester Industries Limited and their joint venture entity Ester Loop Infinite Technologies Private Limited (formed 1 May 2024). Loop grants the JV exclusive license to manufacture rDMT/rMEG and specialty polymers in India using Loop's proprietary depolymerization technology. The JV pays Loop tiered royalties (0–[***]% of net sales, subject to floors/caps ranging $0–$40M+) and marketing services fees ([***]% to [***]%, with floors of $15M–$25M+), calculated on fiscal-year net sales. Loop retains all sales marketing rights; the JV manufactures and fulfills orders. Specific royalty percentages and fee percentages are redacted as confidential. The agreements are perpetual unless terminated under specified conditions (breach, non-payment with 120-day cure, Marketing Agreement termination).

Cycurion announced its largest contract ever: a $54.6M, 10-year state HHS modernization deal (work begins November 2026, revenue Q4 2026, ramping to >$5M annually). The company also closed acquisition of Digital Ally Video Solutions, adding ~$5.5M annual revenue and ~$1.2M EBITDA, with 800+ law enforcement agencies as customers. Pro forma annual revenue run rate post-acquisition is ~$30M. CEO confirmed regained Nasdaq compliance (October 1, 2026) after bid price deficiency. Additional contracts: Chicago public safety (~$843K in 2026, potential $3.43M over 10 years for CAD admin); ~$800K in pharma/healthcare AI engagements. Current share count: ~3.2M common shares outstanding.

On August 3, 2026, Brady Corporation completed its acquisition of Honeywell's Productivity Solutions and Services business for $1.4 billion in cash (net of adjustments), funded by $500M term loan, $304.7M revolving credit draw, and $800M senior notes ($250M at 5.43%, $300M at 5.65%, $250M at 5.90%). PSS is a global hardware/software/automation solutions provider (mobile devices, data capture, cloud software) serving retail, logistics, healthcare; historical FY2025 revenue $1,147M, net income $105M. Brady financed transaction with debt, incurring ~$84M annual interest expense pro forma.

Odyssey Marine Exploration announced the SEC declared effective its Form S-4 registration statement for the proposed merger with American Ocean Minerals Corporation on October 15, 2026. The company will execute a 1-for-25 reverse stock split on October 28, 2026, reducing outstanding shares from ~58.6 million to ~2.3 million; stockholder vote on merger scheduled December 2, 2026. No specific deal valuation, financing amounts, or AOMC shareholder details disclosed in this filing.

Atlantic American Corporation amended its revolving credit facility with Truist Bank via two amendments (Fourth on Oct 9, 2026 and Fifth on Oct 15, 2026). The Fifth Amendment waived two Events of Default: (1) American Southern's AM Best rating downgrade to 'A-' on April 22, 2026, violating Section 8.12 covenant, and (2) failure to promptly notify Lender of the downgrade. Amendments extended financial reporting deadlines (annual audited statements to Oct 23, 2026; quarterly to Nov 30, 2026 for Q1-Q3 2026) and modified the Required Insurance Rating covenant to specify minimum ratings for American Southern ('A-'), Bankers Fidelity Life ('A-'), and Atlantic American itself ('bbb-' long-term issuer). No dollar amount of the facility disclosed in filing.

On July 31, 2026, Deluxe Corporation completed its acquisition of Celero Commerce (a subsidiary of Celero Intermediate Holdings LLC) for approximately $625 million in cash, funded through incremental term loan and revolving credit facility borrowings. Celero is a payment processing and software services provider with $198.8M revenue (2025) and $99.1M revenue (H1 2026). The transaction adds ~$200M of identifiable intangible assets and $387M of goodwill to Deluxe's balance sheet, expanding its payment processing capabilities.

The 8-K indicates termination of a material definitive agreement (Item 1.02), unregistered equity securities sale (Item 3.02), and officer/director changes with compensation arrangements (Item 5.02), all as of October 9, 2026. Specific counterparties, dollar amounts, share counts, and agreement details are not disclosed in this index page; the actual filing documents must be reviewed for concrete figures.

PharmaCyte Biotech's auditor CBIZ CPAs P.C. resigned effective October 16, 2026. The auditor's letter confirms it read and agrees with PharmaCyte's Item 4.01 disclosures but explicitly states it cannot agree or disagree with other statements by the company, suggesting unresolved audit disagreements or scope limitations. No specific financial restatement, dollar amounts, or detailed reasons are disclosed in this exhibit alone.

On 2026-10-15, High Roller Technologies (Las Vegas, NV; ~$8.0M market cap) filed an 8-K disclosing Item 4.02: non-reliance on previously issued financial statements or audit report. The filing provides no specific dollar amounts, percentages, account restatements, or details of the underlying accounting errors or scope of restatement. No quantitative impact or affected periods are disclosed in the available text.

Director Troim Tor Olav (BORR) bought 500K shares (~$2.3M) on the open market (1.2% of holdings). Open-market insider purchase — historically a bullish signal.

Strive, Inc. priced 7,000,000 shares of 15.00% Series A Perpetual SATS Preferred Stock at $90 per share on October 15, 2026, with settlement on October 20, 2026. Gross proceeds of ~$630M will fund bitcoin acquisition, working capital, income-generating assets, and potential Class A common stock repurchases. The preferred stock ranks senior to common equity, accrues cumulative 15% annual dividends, and includes a $22.50/share dividend reserve (18 months of payments) funded from existing cash and securities.

Chief Operating Officer Snowling Harvey Edward (BORR) bought 300K shares (~$1.5M) on the open market (67% of holdings). Open-market insider purchase — historically a bullish signal.

Fox Factory's Board replaced CEO Mike Dennison with independent director Douglas Grimm as Interim CEO effective October 16, 2026. Grimm receives $1.065M annual base salary, $600K completion bonus (earned at 6-month mark or permanent CEO hire), and $3.6M in RSUs ($2M initial + up to $1.6M additional over 12 months if he stays). The company simultaneously slashed Q3 and FY2026 guidance: Q3 net sales now $336–$340M (prior $355–$380M), adjusted EBITDA $38–$42M (prior $46–$54M); full-year sales cut to $1.35–$1.38B (prior $1.42–$1.47B), EBITDA to $140–$150M (prior $176–$196M). Marucci Sports divestiture (closed Sept 25, 2026, ~$63M of guidance reduction) and supply disruptions in Powered Vehicles Group cited as primary headwinds.

KPMG Accountants N.V., the principal auditor for Terra Innovatum Global N.V., was dismissed on October 12, 2026, after reporting on FY2025 consolidated financial statements dated June 15, 2026. KPMG agreed with Terra Innovatum's disclosure of the change but could not confirm audit committee approval. No successor auditor has been named in this filing.

WaFd reported fiscal 2026 net income of $256M (EPS $3.21, +22% YoY) and Q4 net income of $60M (EPS $0.76). Key metrics: transaction deposits +4.6% to $12.9B; active loan originations +7.9% YoY; non-performing assets fell 37% to 0.32% of assets after $36M charge-off on resolved large loan. On September 7, 2026, WaFd announced a definitive merger agreement with EverBank (specific terms not disclosed in this filing). Paid 174th consecutive quarterly dividend of $0.27/share on September 4, 2026. Repurchased 4.7M shares at avg $31.00.

Laser Photonics appointed founder Dmitri Nikitin as Executive Chairman and principal executive officer effective October 12, 2026, replacing Wayne Tupuola who resigned for medical reasons on October 13, 2026. Nikitin receives $400,000 annual base salary, $1,850/month car allowance, 2,000,000 common shares vesting 50% at grant and 50% ratably over two years, plus 12 months severance if terminated without cause. The appointment follows departure of interim President Ann Tewari.

Alector priced an underwritten offering of 36,600,000 shares at $2.05 per share (7.3% premium to Oct 15 close), generating gross proceeds of ~$75.0M. Underwriters: Morgan Stanley and BTIG. Expected close Oct 19, 2026. Investors include TCGX, BVF Partners, ADAR1 Capital, Deep Track Capital. Proceeds for R&D, manufacturing, working capital, and potential acquisitions.

Organovo (tenant) and San Diego Inspire 2 LLC (landlord) amended their lease at 11555 Sorrento Valley Road. Organovo surrenders ~2,892 sq ft (Suite 202) effective February 28, 2027, reducing premises from ~10,943 to ~8,051 sq ft. Lease extended to April 30, 2028 with monthly base rent of $43,072.85; Organovo receives 50% rent abatement ($86,145.70 total) for March–June 2027. Tenant's building share reduced to 30.36%; parking passes reduced to 20.